{"schema_version":"secwatch.filing_event.v1","accession":"0001093557-25-000241","form_type":"8-K","ticker":"DXCM","cik":"0001093557","company_name":"DEXCOM INC","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.319929+00:00","generated_at":"2026-05-17T22:47:57.846475+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.88,"calibrated_materiality_score":0.88,"confidence":"high","headline":"Dexcom Q2 revenue $1.157B (+15% YoY); raises FY25 revenue guidance; CEO Sayer to retire, Jake Leach named CEO","bullets":["Revenue $1.157B (+15% YoY); GAAP EPS $0.45, non-GAAP EPS $0.48.","Raises FY25 revenue guidance to $4.600-4.625B (14-15% growth); margins reiterated.","CEO Kevin Sayer to retire Jan 1, 2026; becomes Executive Chairman. COO Jake Leach promoted to CEO and Board.","FDA clearance for Dexcom G7 15 Day CGM System received in Q2.","U.S. revenue +15%, international +16% reported (+14% organic)."],"urls":{"canonical":"https://secwatch.observer/filing/0001093557-25-000241","json":"https://secwatch.observer/filing/0001093557-25-000241.json","markdown":"https://secwatch.observer/filing/0001093557-25-000241.md","text":"https://secwatch.observer/filing/0001093557-25-000241.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1093557/000109355725000241/0001093557-25-000241-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1093557/000109355725000241/dxcm-20250725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:47:57.846475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}